Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Billaud

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Transplantation|August 27, 2005
C2 versus C0 cyclosporine monitoring: still not the endEliane M Billaud
Therapie|June 22, 2000
Clinical pharmacology of immunosuppressive drugs: year 2000--time for alternativesE M Billaud
Therapie|July 31, 2001
[Therapeutic drug monitoring (TDM): definitions--vocabulary and concepts]E M Billaud
The Journal of Biological Chemistry|February 1, 2000
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathwayC Segouffin-Cariou, M Billaud
Transplantation Proceedings|November 15, 2002
C2 therapeutic drug monitoring of cyclosporine: sources of variabilityE M Billaud, C Antoine
Archives D'Anatomie Et De Cytologie Pathologiques|October 1, 1998
[The RET gene in thyroid pathology]F M Michiels, M Billaud
IARC Scientific Publications|January 1, 1988
Cooperation between cellular and Epstein-Barr virus genes in the genesis of Burkitt's lymphomaA Calender, M Billaud, G Lenoir
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1993
A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteinsM Billaud, K J Isselbacher, R Bernards
Trends in Genetics : TIG|October 5, 2001
The RET receptor: function in development and dysfunction in congenital malformationS Manié, M Santoro, A Fusco, et al.
Current Hypertension Reports|October 14, 2020
Is there any Hope for Monitoring Adherence in an Efficient and Feasible Way for Resistant Hypertension Diagnosis and Follow-Up?Benjamin Kably, Eliane M Billaud, Pierre Boutouyrie, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Transplantation|August 27, 2005
C2 versus C0 cyclosporine monitoring: still not the endEliane M Billaud
Therapie|June 22, 2000
Clinical pharmacology of immunosuppressive drugs: year 2000--time for alternativesE M Billaud
Therapie|July 31, 2001
[Therapeutic drug monitoring (TDM): definitions--vocabulary and concepts]E M Billaud
The Journal of Biological Chemistry|February 1, 2000
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathwayC Segouffin-Cariou, M Billaud
Transplantation Proceedings|November 15, 2002
C2 therapeutic drug monitoring of cyclosporine: sources of variabilityE M Billaud, C Antoine
Archives D'Anatomie Et De Cytologie Pathologiques|October 1, 1998
[The RET gene in thyroid pathology]F M Michiels, M Billaud
IARC Scientific Publications|January 1, 1988
Cooperation between cellular and Epstein-Barr virus genes in the genesis of Burkitt's lymphomaA Calender, M Billaud, G Lenoir
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1993
A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteinsM Billaud, K J Isselbacher, R Bernards
Trends in Genetics : TIG|October 5, 2001
The RET receptor: function in development and dysfunction in congenital malformationS Manié, M Santoro, A Fusco, et al.
Current Hypertension Reports|October 14, 2020
Is there any Hope for Monitoring Adherence in an Efficient and Feasible Way for Resistant Hypertension Diagnosis and Follow-Up?Benjamin Kably, Eliane M Billaud, Pierre Boutouyrie, et al.
Pageof 10